Macular disease
Shares soar as Australian AMD drug outperforms Lucentis
Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone Lucentis...
Read moreDetails
Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone Lucentis...
Read moreDetails